MAXIVAX
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX-ONCO-1. MaxiVAX’ mission is to develop alternative solutions to “established cancer therapies” that are more effective, are personalized and enable the patient to fight his own disease. MaxiVAX’ first treatment, MVX-ONCO-1 has been classified as an Advanced Therapeutic Product by the European Medicines Agency. The resulting approval procedure is different than that of a traditional drug and should generally allow a faster development until market approval with fewer and less extensive clinical trials.
MAXIVAX
Social Links:
Industry:
Biotechnology
Founded:
2005-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.maxivax.ch
Total Employee:
1+
Status:
Active
Contact:
+41 22 552 26 13
Total Funding:
8.07 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt Apple Mobile Web Clips Icon WordPress Font Awesome Apache
Similar Organizations
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Current Employees Featured
Founder
Official Site Inspections
http://www.maxivax.ch Semrush global rank: 5.19 M Semrush visits lastest month: 1.56 K
- Host name: h2web48.infomaniak.ch
- IP address: 128.65.195.87
- Location: Satigny Switzerland
- Latitude: 46.2146
- Longitude: 6.0355
- Timezone: Europe/Zurich
- Postal: 1242
More informations about "MaxiVAX"
MaxiVAX - Crunchbase Company Profile & Funding
MaxiVAX is a Swiss clinical-stage biotechnology company, currently performing a first-in-man (phase I) trial in various tumours with MVX … See details»
MaxiVAX SA - startup.ch
MaxiVAX SA : MaxiVAX was founded by Nicolas Mach (Oncology, HUG in Geneva) and Bernard Mach (ex-University of Geneva & Co-founder of Biogen). Some of its key technology is derived from Patrick Aebischer … See details»
MaxiVAX - BioAlps
Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and Minaris Regenerative Medicine GmbH (“Minaris”), a leading contract development and manufacturing … See details»
MaxiVAX and Minaris Regenerative Medicine Enter into a …
MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy GENEVA, Switzerland and MUNICH, Germany – Feb 22, … See details»
MaxiVAX SA - Geneva, Switzerland - bionity.com
Nov 17, 2014 MaxiVAX is a Geneva-based biotech company developing the first active immunotherapy based on encapsulated cells for treating cancers. The field of Immuno … See details»
MaxiVAX SA - selectscience.net
MaxiVAX is a clinical-stage biotechnology company advancing patient-specific immunomodulatory strategies for the treatment of cancers. The company was founded in 2005 by Prof. Bernard … See details»
MaxiVAX Company Profile - Office Locations, Competitors ... - Craft
MaxiVAX is a company that develops a personalized anti-cancer vaccination designed to build immunity against cancer. The company combines a vaccination process against the complete … See details»
MaxiVAX - VentureRadar
MaxiVAX SA is a clinical stage (Phase II) biotech company dedicated to the cure of cancer by immuno-therapy. ... Find out more about MaxiVAX, Biotechnology and Life Sciences. See details»
MaxiVax S.A. - life-sciences-europe.com
MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. The company received the 2017 CTI … See details»
MaxiVAX - Esprit de Genève
MaxiVAX Recherche-développement en autres sciences naturelles, ingénierie, sciences médicales et agricoles See details»
MaxiVAX Company Information - Funding, Investors, and More
Get information on funding, investors, industries, and more for MaxiVAX. See MaxiVAX company profile and funding data. See details»
MaxiVAX and Minaris Regenerative Medicine Enter into a …
Feb 23, 2021 MaxiVAX and Minaris Regenerative Medicine Enter into a Manufacturing Partnership for MVX-ONCO-2 Cancer Immunotherapy GENEVA, Switzerland and MUNICH, … See details»
PRESS RELEASE - maxivax.ch
About SAKK www.sakk.ch cal Cancer Research (SAKK) is a non-profit organization, which has been conducting clinical trials in oncology since 1965. Its primary objective is to research ew … See details»
PRESS RELEASE - maxivax.ch
MaxiVAX received the 2017 CTI Swiss Medtech Award on 13 June 2017 from Swiss Federal Councillor Johann N. Schneider-Amman. This recognised the work done by both MaxiVAX … See details»
World leaders recommit to immunisation amid global funding …
2 days ago The Global Summit: Health & Prosperity through Immunisation sees a record number of donors pledge towards Gavi, the Vaccine Alliance, securing more than US$ 9 billion … See details»
PRESS RELEASE - maxivax.ch
Geneva, Switzerland – 17 July 2018 – MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announces the appointment of T. Scott … See details»
MaxiVAX and Minaris Regenerative Medicine Enter into a
Feb 24, 2021 GENEVA, Switzerland and MUNICH, Germany – Feb 22, 2021 — MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, and … See details»
MaxiVAX raises additional CHF5 million - startupticker.ch
Nov 27, 2019 MaxiVAX SA, developing novel anti-cancer vaccines, a Series B 2 round of CHF 5 million from new and existing investors. In addition, the company had been awarded a Horizon … See details»
MaxiVAX and Minaris Regenerative Medicine Enter into a …
MaxiVAX SA and Minaris Regenerative Medicine GmbH have entered into a manufacturing agreement for MVX-ONCO-2, a cell-based immunotherapy for the treatment of cancers such … See details»
MEDIENMITTEILUNG - maxivax.ch
Über MaxiVAX www.maxivax.ch MaxiVAX ist ein Schweizer Biotech-Unternehmen mit klinischen Entwicklungsprodukten, das eine völlig neuartige, patientenspezifische und personalisierte … See details»